


# Cytogenetic analyses in malignant hematological disorders



general concepts



Lucienne Michaux

*Lessenreeks*  
21/11/2017



# Plan



- Definition
- History
- Pathophysiology of malignant hematological disorders
- Techniques
  - Conventional cytogenetics
  - Molecular cytogenetics
- Indications of cytogenetic analyses
- Interest of cytogenetic analyses



# Definition

= cell genetics

- Conventional: karyotype (1950-...)
- Molecular: isotopic followed by non isotopic techniques (1985-...):
  - Immuno-enzymatic,
  - immunofluorescence (FISH)

# History

- **1890:** nuclear and mitotic abnormalities in carcinoma cells (*Von Henseman*)
- **1914:** clonal chromosomal aberrations responsible for malignant transformation - theory (*Boveri*)
- **1956:** number of human chromosomes (*Tjio & Levan*)
- **1960:** small « marker » chromosome = « Philadelphia chromosome » in chronic myeloïd leukemia (*Nowell & Hungerford*)







Figure 5 | A human metaphase plate, from the original Tjio and Levan paper, showing 46 chromosomes. Reproduced with permission from REF. 14 © (1956) Blackwell Publishing.




«A minute chromosome in human chronic granulocytic leukemia», *Science*, 1960






- **1970:** chromosomal banding (*Casperson*)
- **1970-....:** discovery of recurrent cytogenetic aberrations; correlations with diagnosis and prognosis
- **1975-....:** development of molecular biology, cloning of involved genes, functional studies
- **1990-....:** 1st therapeutic applications
- **1990-...**improvement of culture techniques and « onset » of molecular cytogenetics → progress +++
  - FISH, variants (microarrays)






- **2001:** human genome mapped (*Human Genome Organisation*)

- **2009:** first whole genome sequencing of an AML (*Mardis*), ...  
→ high-throughput



# Pathophysiology








- Malignant hemopathies are **acquired** diseases characterized by genetic aberrations which persist (= clonality) and accumulate (= clonal evolution)
- **Clonality** detection is useful (☞: clonality ≠ always malignancy)
- Some aberrations are disease-specific

→ Clonality = diagnostic classifier & follow-up tool



# Karyotype

**Principle:** detection of chromosomal aberrations in dividing malignant cells (mitoses; in particular metaphases), using cell biology techniques


Mitosis  $\leq 1$  hour














# Karyotype: steps












G banding (trypsin-Giemsa)




C banding (centromeric,  
Barium hydroxyde)




R banding (reverse:  
heating+ acridine orange)



Q banding (quinacrine)



GTG




RHG

Normal human karyotype :

46 chromosomes



- 22 pairs of autosomes
- 2 gonosomes (XX or XY)



- Aim of karyotype in hemato-oncology = detection and characterization of an abnormal cell population




- **Clone** = cell population originating from the division of an « ancestral cell »
  - *Cytogenetic definition : **at least 2 cells with supernumerary or structurally abnormal chromosomes, at least 3 cells with chromosomal loss.***
  - *often (but not always), monoclonality = malignancy*







Result (karyotype): expressed as a **formula**, according to rules and nomenclature (ISCN 2016)





- Each clone is described separately ( « / » between clones)
- Number of chromosomes (« modal » number) of the clone
- Gonosomes (according to ploidy) and abnormalities
- Autosomes (ascending order: 1→22) and abnormalities
- Number of cells in the clone : [ ]

Ex:

46,XY,t(9;22)(q34;q11)[4]  
/47,idem,+8[3]/46,XY[10]






«;» and «,», «[» and «(» are not the same








# Karyotype

- Overview of genome
- Can miss subtle aberrations
- Requires “abnormal” cell division

# Technical constraints

- Principle: all invaded tissues are suitable...but tissues must be viable, and the target cell capable of proliferation
- Sample: type  ! transport delay , hierarchy of sample distribution, tissue conservation 
- Appropriate culture conditions (duration, mitogens/cytokines)





# Molecular cytogenetics



- Principle: identification of chromosomal abnormalities in malignant cells...but tissues must *not* be viable
- Base: biochemical properties of DNA
- All invaded tissues are suitable
  - ✔ fresh sample: OK
  - ✔ frozen sample: OK
  - ✔ EDTA: OK
  - ✔ fixed tissue: OK (!! duration of fixation)
  - ✔ small tissue: can be OK
  - ✔ sorted cells: OK
  - ✔ FISH + immuno: OK
- Culture conditions adapted *only* in case of metaphase FISH

# FISH: principle



# FISH: targets

## Cell DNA

- Conventional karyotype (smallest band)
- FISH on metaphase chromosomes
- FISH on Interphase nuclei
- FISH on chromatin fibers ("fiber FISH")




resolution

5-10 Mb

$\pm 1$  Mb

$\pm 100$  Kb





$\pm 1$  Kb




## RNA










- FISH can be performed on interphase nuclei → more sensitive than karyotype (more cells can be scored)
- Interphase FISH is possible
  - on cell suspensions/touch prints
  - on archival material
  - in combination with morphology & immunology (FICTion)



# FISH: probes



= labeled nucleic acids  
fragments complementary  
to a specific sequence of  
the genome



Different probes:

- centromeric

- telomeric

- painting (wcp)

- “Locus specific” probes” (*commercial or homemade*)

### Vectors

Plasmids

Phages

Cosmids

Phosmids

P1

PAC (P1-Artificial Chromosomes)

BAC (Bacterial Artificial Chromosomes)

YAC (Yeast Artificial Chromosomes) 2Mb

### Insert size

0,5-5 Kb

9-25 Kb

35-50 Kb




> 40 Kb


70-85 Kb

100-120 Kb


120-150 Kb

200 Kb → >





[www.ensembl.org](http://www.ensembl.org)



National Center for Biotechnology Information

[http://www.ncbi.nlm.nih.gov/mapview/map\\_search.cgi?taxid=9606](http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?taxid=9606)

UCSC Genome Bioinformatics


University of California Santa Cruz

<http://genome.cse.ucsc.edu/cgi-bin/hgGateway>




Ensembl Genome Browser

[http://www.ensembl.org/Homo\\_sapiens/index.html](http://www.ensembl.org/Homo_sapiens/index.html)






# Locus-specific probes: strategies

- breakapart



normal

abnormal







Examples:



- separation/breakapart  
split of *KMT2A*/11q23 in  
an AML with a t(9;11)
- Colocalisation/fusion  
*BCR/ABL* fusion on a  
der(22)t(9;22) in a CML



# Probes: labeling



# Probes: hybridization




TCAGTTCGACTGACTAGCTGAAAGGT  
AGTCAAGGCTGACTGATCGACTTCCAG

★ ★ ★  
CTGACTAGCTGAA  
★ ★ ★  
CTGACTAGCTGAA  
AGTCAAGGCTGACTGATCGACTTCCAG


★ ★ ★  
CTGACTAGCTGAA  
AGTCAAGGCTGACTGATCGACTTCCAG  
**GREAT HOMOLGY**



★ ★ ★  
CTGACTAGCTGGG  
AGTCAAGGCTGACTGATCGACTTCCAG  
**LESS HOMOLGY**

★ ★ ★  
CTGACTGGGGGGG  
AGTCAAGGCTGACTGATCGACTTCCAG  
**LOW HOMOLGY**




# Probes: revelation









Spectrum of excitation




Spectrum of emission





# FISH



- Targeted analysis of region(s) of interest
- Does not necessarily require “abnormal” cell division





- Variants of the FISH technique
  - spectral karyotype / M-FISH
  - M-Band
  - RX-FISH
  - Comparative genomic hybridization (CGH)
  - **Array-CGH**, SNP-array
  - CESH...












# Spectral karyotype / M-FISH

chromosome fluorochromes

#	FITC	SpeOral	TesRed	Cy5	DEAC
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
X					
Y					


mFISH Labelling Scheme  
MetaSystems





$$2^n - 1$$


a



$$\left( n + \frac{r * n!}{2 * (n-2)!} \right)$$

b


# Spectral karyotype / M-FISH




- Overview of genome
- Can miss subtle aberrations
- Requires “abnormal” cell division

# Example M-FISH

→ "Profiles"



chromosome 1



der(1)t(1;7)

Acute promyelocytic leukemia → t-MDS


chromosome

fluorochromes

#	FITC	SpeOra	TexRed	Cy5	DEAC
1				Yellow	
2					Cyan
3			Magenta		
4	Green				
5		Red			
6	Green			Yellow	
7				Yellow	Cyan
8			Magenta		
9		Red		Yellow	
10	Green				Cyan
11	Green		Magenta		
12	Green	Red			
13			Magenta		Cyan
14		Red			Cyan
15		Red	Magenta		
16	Green			Yellow	Cyan
17	Green		Magenta	Yellow	
18	Green	Red		Yellow	
19			Magenta	Yellow	Cyan
20		Red		Yellow	Cyan
21		Red	Magenta	Yellow	
22	Green		Magenta		Cyan
X	Green	Red			Cyan
Y		Red	Magenta		Cyan


mFISH Labelling Scheme  
MetaSystems

# M-Band: example (and principle)




**Metasystems Xcyte 3  
Labeling scheme**

**AML M4**







**G-banding**




**m-BAND chromosome 3**

# FISH: expanding!




# Comparative genomic hybridization (CGH)



- Detects DNA gains/losses
- Does not detect balanced abnormalities
- Does not require cell division

# Comparative genomic hybridation (aCGH) Example: CLL with del(13q)








# Cytogenetic analyses which tool?


- Selection based on
  - type of sample available (fresh/frozen or not, amount, access)
  - type of question (diagnostic set-up vs follow-up of MRD)
  - type of abnormality to screen for (point mutation / specific gene aberration vs genome wide screening)
  - Context: routine vs research



# Cytogenetics: diagnostic value

The World Health Organization (WHO) classification of malignant hemopathies includes cytogenetics

- Some aberrations are subtype specific
- Some aberrations can indicate for the presence of a malignant disorder



# Cytogenetics: prognostic value

Type (and sometimes number) of aberrations = major prognostic factor → « stratified » treatments



Clonal evolution: often predicts poor outcome



# Indications of cytogenetic analyses

	Diagnostic	FU	Prognostic
AML	+	+/-	+
ALL	+	+/-	+
MDS	+/-	+/-	+
CML	+++	+++	+
MPN (other)	+	+/-	-
NHL	+	-	-
CLL	+/-	+	+
MM	+/-	+/-	+



## Other...



- pathophysiology
- & therapy!



Atlas of cytogenetics (contains informations on clinico-biological entities and on specific chromosome aberrations) :

<http://atlasgeneticsoncology.org/>

WHO 2017



Catalog of genetic anomalies in cancer (useful in case of very rare aberrations)

<http://cgap.nci.nih.gov/Chromosomes/Mitelman>

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447.

Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.

Wolach O, Amitai I, DeAngelo DJ.

Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14916. [Epub ahead of print]



**Reading can  
seriously damage  
your ignorance**

